Discover the little-known medtech company that Zacks SCR has issued a price target of $32.50!
While the markets have been volatile and unpredictable, one underfollowed biotech stock has been making great strides. Consider adding BioStem Technologies (OTC: BSEM) to your portfolio; a leading innovator in the manufacturing and commercialization of allografts for regenerative therapies.
Throughout the last year Zacks Small Cap Research has been very bullish on BSEM and has been lifting its price target several times. Most recently the firm gave BSEM a price target of $32.50, a tremendous upside potential from current levels.
Why is Zacks so optimistic? Because Zacks believes that the company is well on its way to achieving that goal—providing to investors what the firm believes is an opportunity to invest in a company that is both providing a vital service to the human population and providing economic value to shareholders when doing so. BSEM also continues to release positive news, both for its investors and patients alike.
Earlier this quarter, BSEM management preannounced preliminary results that showed record 4Q net revenues. If this is confirmed in the soon-to-be-released 2024 fiscal results, Zack's could be ready to lift its price target yet again.
Additionally, the company continues the process of uplisting its stock to the NASDAQ stock exchange, which should improve access and liquidity for investors in BSEM.
The company also just announced that its proprietary amnion chorion allograft, known as BioRetain has been approved by the Institutional Review Board (IRB) for the treatment of venous leg ulcers. This follows the announcement of the publication of a peer-reviewed study showing breakthrough results regarding the application of this product for diabetic foot ulcers.
Discover why BSEM is a company to put high on your radar, especially if Zacks lifts its price target again when 2024 fiscal results are out!
This message is a PAID ADVERTISEMENT for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. StockEarnings, Inc. has received a fixed fee of $6000 from Sideways Frequency for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between March 27, 2025 and April 2, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies Inc. (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies Inc. (OTC: BSEM).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
No comments:
Post a Comment